Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2019

01.10.2018 | Original Article

Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn’s Disease

verfasst von: Patrick Althoff, Wolff Schmiegel, Gernot Lang, Volkmar Nicolas, Thorsten Brechmann

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Crohn’s disease (CD) leads to bowel damage and surgery in a significant proportion of patients.

Aims

The aim of the study was to evaluate the predictive value of creeping fat assessed by small bowel MRI in CD patients.

Methods

CD patients undergoing small bowel MRI were included in a retrospective observational cohort study. Clinical findings were extracted and correlated with radiological outcome measures. Logistic regression analysis was performed to assess predictors associated with a complicated course and surgery within 2 years and long-term follow-up.

Results

Ninety patients (49% female, median follow-up 93 months) were included. Creeping fat was identified in 21.1%. Of these patients, 68% and 79% developed bowel damage (p < .05) and 42% and 63% of patients revealing creeping fat underwent surgery within 2 years following MRI and total follow-up, respectively. The presence of creeping fat [odds ratio (OR) 4.0], inflammatory stenosis (OR 3.7), multisegmental (small) bowel (OR 4.5 and 3.8), and proximal small bowel inflammation (OR 5.0) were associated with inferior outcome (p < .05) in a univariate analysis. Creeping fat was independently associated with a disabling course, bowel damage, and surgery (OR 3.5 each, p < .05) in a multivariate analysis model.

Conclusion

Creeping fat identified by small bowel MRI is associated with a complicated course and abdominal surgery in CD. Our data adds evidence that small bowel MRI facilitates risk stratification in order to define a patient at risk of disease-related complications in CD. [DRKS00011727, www.​germanctr.​de/​].
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Peyrin-Biroulet L, Loftus EV, Colombel JF, et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2009;105:289–297.CrossRef Peyrin-Biroulet L, Loftus EV, Colombel JF, et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2009;105:289–297.CrossRef
2.
Zurück zum Zitat Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–1605.CrossRef Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–1605.CrossRef
3.
Zurück zum Zitat Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. Gut. 2011;60:1754–1763.CrossRef Ordás I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. Gut. 2011;60:1754–1763.CrossRef
4.
Zurück zum Zitat Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut. 2011;60:930–936.CrossRef Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut. 2011;60:930–936.CrossRef
5.
Zurück zum Zitat Safroneeva E, Vavricka SR, Fournier N, et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn’s disease. Aliment Pharmacol Ther. 2015;42:977–989.CrossRef Safroneeva E, Vavricka SR, Fournier N, et al. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn’s disease. Aliment Pharmacol Ther. 2015;42:977–989.CrossRef
6.
Zurück zum Zitat Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn’s disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol. 2012;107:1693–1701.CrossRef Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn’s disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol. 2012;107:1693–1701.CrossRef
7.
Zurück zum Zitat Rogler G, Bernstein CN, Sood A, et al. Role of biological therapy for inflammatory bowel disease in developing countries. Gut. 2012;61:706–712.CrossRef Rogler G, Bernstein CN, Sood A, et al. Role of biological therapy for inflammatory bowel disease in developing countries. Gut. 2012;61:706–712.CrossRef
8.
Zurück zum Zitat Antunes O, Filippi J, Hébuterne X, et al. Treatment algorithms in Crohn’s—up, down or something else? Best Pract Res Clin Gastroenterol. 2014;28:473–483.CrossRef Antunes O, Filippi J, Hébuterne X, et al. Treatment algorithms in Crohn’s—up, down or something else? Best Pract Res Clin Gastroenterol. 2014;28:473–483.CrossRef
9.
Zurück zum Zitat Singh S, Loftus EV. Crohn’s disease: REACT to save the gut. Lancet. 2015;386:1800–1802.CrossRef Singh S, Loftus EV. Crohn’s disease: REACT to save the gut. Lancet. 2015;386:1800–1802.CrossRef
10.
Zurück zum Zitat Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis. 2012;30:67–72.CrossRef Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis. 2012;30:67–72.CrossRef
11.
Zurück zum Zitat Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016;10:1385–1394.CrossRef Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016;10:1385–1394.CrossRef
12.
Zurück zum Zitat Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139:1147–1155.CrossRef Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139:1147–1155.CrossRef
13.
Zurück zum Zitat Aldhous MC, Drummond HE, Anderson N, et al. Does cigarette smoking influence the phenotype of Crohn’s disease? Analysis using the Montreal classification. Am J Gastroenterol. 2007;102:577–588.CrossRef Aldhous MC, Drummond HE, Anderson N, et al. Does cigarette smoking influence the phenotype of Crohn’s disease? Analysis using the Montreal classification. Am J Gastroenterol. 2007;102:577–588.CrossRef
14.
Zurück zum Zitat Kredel LI, Batra A, Stroh T, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn’s disease. Gut. 2013;62:852–862.CrossRef Kredel LI, Batra A, Stroh T, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn’s disease. Gut. 2013;62:852–862.CrossRef
15.
Zurück zum Zitat Schäffler A, Herfarth H. Creeping fat in Crohn’s disease: travelling in a creeper lane of research? Gut. 2005;54:742–744.CrossRef Schäffler A, Herfarth H. Creeping fat in Crohn’s disease: travelling in a creeper lane of research? Gut. 2005;54:742–744.CrossRef
16.
Zurück zum Zitat Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis; a pathologic and clinical entity. Am J Med. 1952;13:583–590.CrossRef Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis; a pathologic and clinical entity. Am J Med. 1952;13:583–590.CrossRef
17.
Zurück zum Zitat Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn’s disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79:955–958.CrossRef Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn’s disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79:955–958.CrossRef
18.
Zurück zum Zitat Golder WA. The “creeping fat sign”—really diagnostic for Crohn’s disease? Int J Colorectal Dis. 2009;24:1–4.CrossRef Golder WA. The “creeping fat sign”—really diagnostic for Crohn’s disease? Int J Colorectal Dis. 2009;24:1–4.CrossRef
19.
Zurück zum Zitat Borley NR, Mortensen NJ, Jewell DP, et al. The relationship between inflammatory and serosal connective tissue changes in ileal Crohn’s disease: evidence for a possible causative link. J Pathol. 2000;190:196–202.CrossRef Borley NR, Mortensen NJ, Jewell DP, et al. The relationship between inflammatory and serosal connective tissue changes in ileal Crohn’s disease: evidence for a possible causative link. J Pathol. 2000;190:196–202.CrossRef
20.
Zurück zum Zitat Spinelli A, Fiorino G, Bazzi P, et al. Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn’s disease. J Gastrointest Surg. 2014;18:8390–8391. (discussion).CrossRef Spinelli A, Fiorino G, Bazzi P, et al. Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn’s disease. J Gastrointest Surg. 2014;18:8390–8391. (discussion).CrossRef
21.
Zurück zum Zitat Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34:125–145.CrossRef Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34:125–145.CrossRef
22.
Zurück zum Zitat Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759–1768.CrossRef Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759–1768.CrossRef
23.
Zurück zum Zitat Lang G, Schmiegel W, Nicolas V, et al. Impact of small bowel MRI in routine clinical practice on staging of Crohn’s disease. J Crohns Colitis. 2015;9:784–794.CrossRef Lang G, Schmiegel W, Nicolas V, et al. Impact of small bowel MRI in routine clinical practice on staging of Crohn’s disease. J Crohns Colitis. 2015;9:784–794.CrossRef
24.
Zurück zum Zitat García-Bosch O, Ordás I, Aceituno M, et al. Comparison of diagnostic accuracy and impact of magnetic resonance imaging and colonoscopy for the management of Crohn’s disease. J Crohns Colitis. 2016;10:663–669.CrossRef García-Bosch O, Ordás I, Aceituno M, et al. Comparison of diagnostic accuracy and impact of magnetic resonance imaging and colonoscopy for the management of Crohn’s disease. J Crohns Colitis. 2016;10:663–669.CrossRef
25.
Zurück zum Zitat Rimola J, Planell N, Rodríguez S, et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015;110:432–440.CrossRef Rimola J, Planell N, Rodríguez S, et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015;110:432–440.CrossRef
26.
Zurück zum Zitat Bouhnik Y, Carbonnel F, Laharie D, et al. GETAID CREOLE Study Group. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018;67:53–60.CrossRef Bouhnik Y, Carbonnel F, Laharie D, et al. GETAID CREOLE Study Group. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018;67:53–60.CrossRef
27.
Zurück zum Zitat Jauregui-Amezaga A, Rimola J, Ordás I, et al. Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn’s disease in the era of biologics. Gut. 2015;64:1397–1402.CrossRef Jauregui-Amezaga A, Rimola J, Ordás I, et al. Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn’s disease in the era of biologics. Gut. 2015;64:1397–1402.CrossRef
28.
Zurück zum Zitat Fiorino G, Morin M, Bonovas S, et al. Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn’s disease and its impact on disease outcome. J Crohns Colitis. 2017;11:274–280.CrossRef Fiorino G, Morin M, Bonovas S, et al. Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn’s disease and its impact on disease outcome. J Crohns Colitis. 2017;11:274–280.CrossRef
29.
Zurück zum Zitat Pauls S, Kratzer W, Rieber A, et al. Quantifying the inflammatory activity in Crohn’s disease using CE dynamic MRI. Rofo. 2003;175:1093–1099.CrossRef Pauls S, Kratzer W, Rieber A, et al. Quantifying the inflammatory activity in Crohn’s disease using CE dynamic MRI. Rofo. 2003;175:1093–1099.CrossRef
30.
Zurück zum Zitat Amitai MM, Raviv-Zilka L, Hertz M, et al. Main imaging features of Crohn’s disease: agreement between MR-enterography and CT-enterography. Isr Med Assoc J. 2015;17:293–297.PubMed Amitai MM, Raviv-Zilka L, Hertz M, et al. Main imaging features of Crohn’s disease: agreement between MR-enterography and CT-enterography. Isr Med Assoc J. 2015;17:293–297.PubMed
31.
Zurück zum Zitat Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflamm Bowel Dis. 2011;17:1073–1080.CrossRef Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflamm Bowel Dis. 2011;17:1073–1080.CrossRef
32.
Zurück zum Zitat Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn’s disease: towards disease modification trials. Gut. 2017;66:2179–2187.CrossRef Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn’s disease: towards disease modification trials. Gut. 2017;66:2179–2187.CrossRef
33.
Zurück zum Zitat Dias CC, Rodrigues PP, Coelho R, et al. Development and validation of risk matrices for Crohn’s disease outcomes in patients who underwent early therapeutic interventions. J Crohns Colitis. 2017;11:445–453.CrossRef Dias CC, Rodrigues PP, Coelho R, et al. Development and validation of risk matrices for Crohn’s disease outcomes in patients who underwent early therapeutic interventions. J Crohns Colitis. 2017;11:445–453.CrossRef
34.
Zurück zum Zitat Koh DM, Miao Y, Chinn RJ, et al. MR imaging evaluation of the activity of Crohn’s disease. AJR Am J Roentgenol. 2001;177:1325–1332.CrossRef Koh DM, Miao Y, Chinn RJ, et al. MR imaging evaluation of the activity of Crohn’s disease. AJR Am J Roentgenol. 2001;177:1325–1332.CrossRef
35.
Zurück zum Zitat Peyrin-Biroulet L, Billioud V, D’Haens G, et al. Development of the Paris definition of early Crohn’s disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107:1770–1776.CrossRef Peyrin-Biroulet L, Billioud V, D’Haens G, et al. Development of the Paris definition of early Crohn’s disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107:1770–1776.CrossRef
36.
Zurück zum Zitat Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5–36.CrossRef Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5–36.CrossRef
37.
Zurück zum Zitat Drouet M, Dubuquoy L, Desreumaux P, et al. Visceral fat and gut inflammation. Nutrition. 2012;28:113–117.CrossRef Drouet M, Dubuquoy L, Desreumaux P, et al. Visceral fat and gut inflammation. Nutrition. 2012;28:113–117.CrossRef
38.
Zurück zum Zitat Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–250.CrossRef Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–250.CrossRef
39.
Zurück zum Zitat Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut. 2009;58:1113–1120.CrossRef Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut. 2009;58:1113–1120.CrossRef
40.
Zurück zum Zitat Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759–1768.CrossRef Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759–1768.CrossRef
41.
Zurück zum Zitat Baraniskin A, Van Laethem JL, Wyrwicz L, et al. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. Eur J Cancer. 2017;86:305–317.CrossRef Baraniskin A, Van Laethem JL, Wyrwicz L, et al. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. Eur J Cancer. 2017;86:305–317.CrossRef
42.
Zurück zum Zitat Deepak P, Fletcher JG, Fidler JL, et al. Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn’s disease. Am J Gastroenterol. 2016;111:997–1006.CrossRef Deepak P, Fletcher JG, Fidler JL, et al. Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn’s disease. Am J Gastroenterol. 2016;111:997–1006.CrossRef
Metadaten
Titel
Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn’s Disease
verfasst von
Patrick Althoff
Wolff Schmiegel
Gernot Lang
Volkmar Nicolas
Thorsten Brechmann
Publikationsdatum
01.10.2018
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2019
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5303-1

Weitere Artikel der Ausgabe 1/2019

Digestive Diseases and Sciences 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.